Gilead Sciences, Inc. $GILD Shares Bought by Fisher Asset Management LLC

Fisher Asset Management LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 143.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,052 shares of the biopharmaceutical company’s stock after purchasing an additional 15,352 shares during the quarter. Fisher Asset Management LLC’s holdings in Gilead Sciences were worth $2,892,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Davis R M Inc. purchased a new stake in Gilead Sciences during the third quarter worth $210,000. Bahl & Gaynor Inc. raised its position in shares of Gilead Sciences by 13.6% in the third quarter. Bahl & Gaynor Inc. now owns 2,447 shares of the biopharmaceutical company’s stock worth $272,000 after acquiring an additional 293 shares during the period. Holderness Investments Co. boosted its stake in shares of Gilead Sciences by 1.2% during the 3rd quarter. Holderness Investments Co. now owns 10,788 shares of the biopharmaceutical company’s stock worth $1,197,000 after acquiring an additional 130 shares in the last quarter. Aprio Wealth Management LLC grew its position in shares of Gilead Sciences by 3.0% during the 3rd quarter. Aprio Wealth Management LLC now owns 12,074 shares of the biopharmaceutical company’s stock valued at $1,340,000 after acquiring an additional 352 shares during the period. Finally, Trivium Point Advisory LLC increased its stake in shares of Gilead Sciences by 1.1% in the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after purchasing an additional 83 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 2.1%

Shares of GILD stock opened at $145.14 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The firm has a market capitalization of $180.18 billion, a P/E ratio of 21.44, a PEG ratio of 1.94 and a beta of 0.37. The stock’s fifty day moving average is $137.91 and its two-hundred day moving average is $125.56. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period last year, the firm posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. The ex-dividend date is Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is presently 46.68%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research report on Monday, February 23rd. Mizuho increased their target price on Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Scotiabank lifted their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research note on Wednesday, February 11th. Argus upped their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Finally, Morgan Stanley lifted their target price on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $156.72.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total value of $463,290.00. Following the completion of the sale, the chief financial officer owned 167,779 shares of the company’s stock, valued at approximately $25,910,110.97. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the sale, the insider owned 120,288 shares of the company’s stock, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 309,280 shares of company stock valued at $43,935,470 over the last ninety days. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.